Key statistics dashboard for Orchestra BioMed Holdings, Inc. (OBIO). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures.
Stock Data
| Price | $6.01 |
| Market Cap | $360M |
| Enterprise Value | $410.2M |
| Beta | 0.60 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -6.11 |
| Price / Book | 13.11 |
| P/S | 11.32 |
| EV/EBITDA | -7.18 |
| EV/Sales | 12.83 |
| EV/FCF | -6.94 |
| P/FCF | -6.12 |
| Earnings Yield | -15.39% |
| FCF Yield | -16.42% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 99.32% |
| EBIT Margin | -179.65% |
| EBITDA Margin | -178.56% |
| Operating Margin | -181.36% |
| Net Margin | -184.60% |
| Return on Equity | -125.93% |
| Return on Assets | -51.02% |
| Return on Invested Capital | -56.28% |
| Return on Capital Employed | -56.73% |
Financial Health
| Current Ratio | 8.26 |
| Quick Ratio | 8.24 |
| Cash Ratio | 1.52 |
| Debt / Equity | 2.41 |
| Debt / Assets | 61.16% |
| Net Debt / EBITDA | -0.88 |
| Interest Coverage | -27.63 |
Per-Share Data
| Revenue per share | 0.50 |
| Book Value per share | 0.46 |
| Cash per share | 1.72 |
| FCF per share | -0.93 |
| Tangible Book Value per share | 0.46 |
| Dividend per share | 0.00 |
Related companies: AVTX · CRBU · ENTA · EPRX · IVA · IVVD · PRLD
Explore sector: Healthcare · Biotechnology
More sections of OBIO: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks